Home / Oncology (page 2)

Oncology

Study Published by Clinical Cancer Research Shows PGDx’s Liquid Biopsy Predictive of PD-1 Blockade Response

BALTIMORE–(BUSINESS WIRE)–A study published by Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), shows Personal Genome Diagnostics Inc.’s (PGDx) liquid biopsy technology successfully detected microsatellite instability (MSI) in circulating tumor DNA (ctDNA), and was able to estimate the likelihood of both an immediate and durable response …

Read More »

VBI Vaccines Partners with GSK to Evaluate a Combination Regimen for Patients with Recurrent Glioblastoma

CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system. As part of the collaboration, VBI plans to …

Read More »

AVEO Oncology Announces Updated Overall Survival Results in Phase 3 Trial of Tivozanib in Renal Cell Carcinoma

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. TIVO-3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma (RCC). …

Read More »

Genmab and Tempus Enter into Strategic Collaboration for Development of Novel Cancer Targets

Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.The multi-year collaboration will combine Tempus’ sequencing capabilities and industry-leading platform of integrated clinical and molecular data with …

Read More »

Adaptimmune’s SPEAR T-cells Targeting MAGE-A4 Granted Orphan Drug Designation from the FDA for Treatment of Soft Tissue Sarcomas

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SPEAR T-cells targeting MAGE-A4 (Adaptimmune’s ADP-A2M4 program) for the …

Read More »

Thermo Fisher Scientific Signs Agreement with Lilly for Companion Diagnostic to be Used with RET Inhibitor

CARLSBAD, Calif., Sept. 9, 2019 /PRNewswire/ — Thermo Fisher Scientific today announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved, next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and thyroid …

Read More »

Bristol-Myers Squibb Provides Update on Phase 3 Trial of Opdivo in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -548 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus the standard of care alone did not meet one of its primary endpoints, progression-free survival (PFS), in patients with newly …

Read More »

FDA Grants Breakthrough Device Designation to Prescient Metabiomics’ LifeKit Prevent Test for Early Detection of Colon Polyps and Colon Cancer

CARLSBAD, Calif., Sept. 4, 2019 /PRNewswire/ — Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted the company’s submission for Breakthrough Device designation to its LifeKit® Prevent Colorectal Neoplasia Test. This Breakthrough Device designation …

Read More »

AbbVie and Idera Enter Immuno-Oncology Clinical Research Collaboration

EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global, research-based biopharmaceutical company.  The purpose of the collaboration is to conduct a clinical study evaluating whether combinations of an OX40 agonist …

Read More »

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Investigational MEK Inhibitor

Ingelheim, Germany and Mumbai, India – 4 September 2019 – Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in …

Read More »